RGDV is a tetrapeptide that delivers attached compounds to targets such as thrombus or tumor cells; it enhances efficacy of anticancer and anti-aggregation or anti-adhesion compounds. RDGV binds integrins on the surfaces of cells and prevents binding of fibrinogen to platelets.
| Cas No. | 93674-99-8 |
|---|---|
| Purity | ≥98% |
| Formula | C17H31N7O7 |
| Formula Wt. | 445.5 |
| Chemical Name | Arginyl-glycyl-aspartyl-valine |
| IUPAC Name | (2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid |
| Synonym | Rgdv tetrapeptide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | R2514 MSDS PDF |
|---|---|
| Info Sheet | R2514 Info Sheet PDF |
Jin S, Wang Y, Zhu H, et al. Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide. ACS Nano. 2013 Sep 24;7(9):7664-73. PMID: 23931063.
Wang F, Cui C, Ren Z, et al. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif. J Pharm Sci. 2012 Dec;101(12):4559-68. PMID: 23023730.
Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities. Prep Biochem Biotechnol. 2002 Nov;32(4):363-80. PMID: 12455829.
Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.
Park HS, Kim C, Kang YK. Biopolymers. 2002 Apr 15;63(5):298-313. PMID: 11877740.
